Cargando…
Expression-Based Diagnosis, Treatment Selection, and Drug Development for Breast Cancer
There is currently no gene expression assay that can assess if premalignant lesions will develop into invasive breast cancer. This study sought to identify biomarkers for selecting patients with a high potential for developing invasive carcinoma in the breast with normal histology, benign lesions, o...
Autores principales: | Ye, Qing, Wang, Jiajia, Ducatman, Barbara, Raese, Rebecca A., Rogers, Jillian L., Wan, Ying-Wooi, Dong, Chunlin, Padden, Lindsay, Pugacheva, Elena N., Qian, Yong, Guo, Nancy Lan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342177/ https://www.ncbi.nlm.nih.gov/pubmed/37445737 http://dx.doi.org/10.3390/ijms241310561 |
Ejemplares similares
-
MicroRNA, mRNA, and Proteomics Biomarkers and Therapeutic Targets for Improving Lung Cancer Treatment Outcomes
por: Ye, Qing, et al.
Publicado: (2023) -
MicroRNA-Based Discovery of Biomarkers, Therapeutic Targets, and Repositioning Drugs for Breast Cancer
por: Ye, Qing, et al.
Publicado: (2023) -
Identification of Prognostic and Chemopredictive microRNAs for Non-Small-Cell Lung Cancer by Integrating SEER-Medicare Data
por: Ye, Qing, et al.
Publicado: (2021) -
A smoking-associated 7-gene signature for lung cancer diagnosis and prognosis
por: WAN, YING-WOOI, et al.
Publicado: (2012) -
Hybrid Models Identified a 12-Gene Signature for Lung Cancer Prognosis and Chemoresponse Prediction
por: Wan, Ying-Wooi, et al.
Publicado: (2010)